Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (561)	10/13/2003 2:21:05 AM
From: Icebrg	Read Replies (2) \| Respond to of 1022

Borean Pharma Accomplishes Major Technological Achievement Monday October 13, 2:00 am ET AARHUS, Denmark, Oct. 13 /PRNewswire/ -- Borean Pharma A/S, the Aarhus- based biopharmaceutical and protein engineering company, today announced that it has reached a key technological milestone by producing protein products with high affinity binding in the 100 - 200 picomolar range. These results demonstrate that Borean's proprietary technology platform is capable of generating fully matured and optimized biopharmaceutical product candidates of a novel class in record time. "I am extremely pleased by the progress that our development team has accomplished ahead of schedule. This achievement is firm evidence that our antibody-analogue technology can produce products rivaling even the best antibody products, both in terms of binding strength and specificity," said Hans Christian Thogersen, Borean's Chief Scientific Officer and Founder. "Most importantly, these results also show that Borean's antibody analogue molecules can be developed and fully matured with much higher efficiency and speed than anyone has ever managed. In terms of affinity-maturation of a product candidate, we have accomplished in four weeks what the antibody developers need 6-12 months to accomplish; and in terms of obtaining the first milligrams of pure final product, we have the advantage inherent to our bacterial expression/processing technology, which reduces that time frame from several weeks to several days." "I am very excited about these impressive results and the limited amount of time that it took to produce them," continued Johanna Holldack, recently appointed as Chief Operating Officer of Borean Pharma. "The high affinity binding is the most important prerequisite for the development of a highly efficacious product and these results are a significant step forward on the road from an innovative technology platform to the development of an important new medical product." Riku Rautsola, Chief Executive Officer of Borean Pharma added, "We are very pleased because this high affinity data is on a target that is highly relevant medically. In particular, these results validate Borean Pharma's leadership in the exciting growth area of recombinant protein engineering and we believe recombinant antibody analogues are the antibody successors of the future, both for therapeutic and diagnostic purposes." About Borean Pharma Borean Pharma was established with the objective to develop a new generation of pharmaceutical protein products. The company's competitive advantage lies in its proprietary technology, enabling it to develop a new generation of highly efficacious antibody analogues that can be produced in E.coli. The ease of production addresses a major shortcoming of monoclonal antibodies. Borean believes that it can unleash the true potential of biologicals by providing efficacious and cost-effective protein-based antibody analogues. Borean Pharma focuses on indications and targets respectively, for which biologicals have already a proven track record and significant sales as drugs, decreasing the development risk.